MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2020

    Opicapone as First-Line Adjunctive Levodopa Treatment in Parkinson’s Disease Patients with Motor Fluctuations: Findings from BIPARK-I and II Combined Post-Hoc Analysis

    J. Ferreira, W. Poewe, A. Antonini, H. Gama, J.F Rocha, D. Magalhães, P. Soares-da-Silva (Lisbon, Portugal)

    Objective: This exploratory post-hoc analysis evaluated the efficacy and safety of opicapone (OPC) as first-line adjunctive therapy in levodopa/DOPA decarboxylase inhibitors-treated Parkinson’s disease (PD) patients…
  • MDS Virtual Congress 2020

    Effects of onabotulinum toxin A on balance and gait in Parkinson’s disease with foot dystonia: A case series study

    P. Huang, YY. Li, P. Huang, Q. Xiao, Y. Wang, S. Chen, S.D Chen, J. Liu, Y.W Wu (Shanghai, China)

    Objective: To investigate the effectiveness of botulinum toxin (BoNT) in reducing the severity of dystonia and improving gait and balance in Parkinson’s disease (PD) patients…
  • MDS Virtual Congress 2020

    Beta-adrenoreceptor medications and risk of Parkinson’s disease

    X. Li, L. Wang, Y. Zhang (Guangzhou, China)

    Objective: To review and analyze the associations between β-adrenoreceptor medications and risk of Parkinson's disease. Background: Distinctive Lewy body mainly composed of α-synuclein is an…
  • MDS Virtual Congress 2020

    Opicapone in Clinical Practice in Parkinson’s Disease Patients with Motor Fluctuations: Findings from the OPTIPARK Study

    H. Reichmann, A. Lees, J.F Rocha, D. Magalhães, P. Soares-da-Silva (Dresden, Germany)

    Objective: This real-world study evaluated opicapone (OPC) 50-mg in a heterogeneous population of Parkinson’s disease (PD) patients treated in clinical practice. Background: OPC proved effective…
  • MDS Virtual Congress 2020

    Efficacy and safety of levodopa-carbidopa intestinal gel (LCIG) for advanced Parkinson’s disease: a Turkish single-centre experience

    Y. Sucullu Karadag (Ankara, Turkey)

    Objective: This study is aimed to investigate the efficacy and adverse effect profile of LCIG among advanced PD patients from a Turkish movement disorder center.…
  • MDS Virtual Congress 2020

    Laryngeal movement disorders as a potential clinical biomarker in multiple system atrophy: Results from the LaPD study

    F. Gandor, A. Vogel, I. Claus, S. Ahring, D. Gruber, H.J Heinze, R. Dziewas, G. Ebersbach, T. Warnecke (Beelitz-Heilstätten, Germany)

    Objective: To systematically assess frequency and nature of laryngeal dysfunction in multiples system atrophy (MSA) compared to Parkinson’s disease (PD) and to identify a potential…
  • MDS Virtual Congress 2020

    GCI-induced neurodegeneration and synucleinopathy in non-human primates

    M. Teil, S. Dovero, M.L Artocarena, M. Bourdenx, G. Porras, B. Mollenhauer, M.T Herrero, M. Vila, J. Obeso, B. Dehay, E. Bezard (Bordeaux, France)

    Objective: This study aimed at determining the potential to induce MSA pathology in non-human primates. Background: Aggregation of alpha-synuclein has been implicated in several neurodegenerative…
  • MDS Virtual Congress 2020

    Can we stage tau pathology in PSP?

    G. Kovacs, M. Lukic, D. Irwin, T. Arzberger, G. Respondek, E. Lee, D. Coughlin, A. Giese, M. Grossman, C. Kurz, C. McMillan, E. Gelpi, Y. Compta, J. van Swieten, C. Troakes, S. Al-Sarraj, J. Robinson, S. Roeber, S. Xie, V. Lee, J. Trojanowski, G. Höglinger (Phildelphia, PA, USA)

    Objective: To evaluate distribution pattern of tau pathology in different PSP clinical subtypes and develop a staging system. Background: Progressive supranuclear palsy (PSP) is a…
  • MDS Virtual Congress 2020

    The effect of comorbid NPH on the clinical feature and progression of Parkinson’s disease

    A. Hattori, T. Tsunemi, Y. Ishiguro, N. Hattori (Tokyo, Japan)

    Objective: To analyze the effect of co-existing normal pressure hydrocephalus (NPH) on the clinical course of Parkinson's disease (PD), we examined the disease progression and…
  • MDS Virtual Congress 2020

    Serum neurofilament light chain differentiates early Parkinson’s disease from progressive supranuclear palsy-parkinsonism

    R. Yadav, P. Ramaswamy, P. Pal, R. Christopher (Bengaluru, India)

    Objective: To assess the value of serum neurofilament light chain (NFL) levels in differentiating parkinsonian syndromes. Background: The diagnosis of Parkinson’s disease (PD) mostly relies…
  • « Previous Page
  • 1
  • …
  • 73
  • 74
  • 75
  • 76
  • 77
  • …
  • 149
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley